138 related articles for article (PubMed ID: 3172354)
1. Hypocalcemia associated with estrogen therapy for metastatic adenocarcinoma of the prostate.
Vogelgesang SA; McMillin JM
J Urol; 1988 Nov; 140(5):1025-7. PubMed ID: 3172354
[TBL] [Abstract][Full Text] [Related]
2. Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
Gulley JL; Wu S; Arlen PM; Dahut WL
Clin Genitourin Cancer; 2007 Sep; 5(6):403-5. PubMed ID: 17956715
[TBL] [Abstract][Full Text] [Related]
3. Estramustine-related hypocalcemia in patients with prostate carcinoma and osteoblastic metastases.
Park DS; Vassilopoulou Sellin R; Tu S
Urology; 2001 Jul; 58(1):105. PubMed ID: 11445494
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease.
Tucci M; Mosca A; Lamanna G; Porpiglia F; Terzolo M; Vana F; Cracco C; Russo L; Gorzegno G; Tampellini M; Torta M; Reimondo G; Poggio M; Scarpa RM; Angeli A; Dogliotti L; Berruti A
Prostate Cancer Prostatic Dis; 2009; 12(1):94-9. PubMed ID: 18332901
[TBL] [Abstract][Full Text] [Related]
5. Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer.
Milat F; Goh S; Gani LU; Suriadi C; Gillespie MT; Fuller PJ; Teede HJ; Strickland AH; Allan CA
Bone; 2013 Aug; 55(2):305-8. PubMed ID: 23685544
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.
Patel K; Brahmbhatt V; Ramu V
Tenn Med; 2005 Feb; 98(2):83-5, 89. PubMed ID: 15779196
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of high-dose estrogens (diethylstilbestrol diphosphate) in prostate cancer.
Citrin DL; Kies MS; Wallemark CB; Khandekar J; Kaplan E; Camacho F; Lind R
Cancer; 1985 Aug; 56(3):457-60. PubMed ID: 4005808
[TBL] [Abstract][Full Text] [Related]
8. Profound hypocalcaemia associated with oestrogen treatment of carcinoma of the prostate.
Harley HA; Mason R; Phillips PJ
Med J Aust; 1983 Jul; 2(1):41-2. PubMed ID: 6865830
[TBL] [Abstract][Full Text] [Related]
9. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
Laskowski LK; Goldfarb DS; Howland MA; Kavcsak K; Lugassy DM; Smith SW
J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
[TBL] [Abstract][Full Text] [Related]
10. Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake?
Ho JW; Sundar S
Clin Genitourin Cancer; 2012 Mar; 10(1):50-3. PubMed ID: 22245101
[No Abstract] [Full Text] [Related]
11. Hypocalcemia with osteoblastic metastases in patient with prostate carcinoma. A cause of secondary hyperparathyroidism.
Smallridge RC; Wray HL; Schaaf M
Am J Med; 1981 Jul; 71(1):184-8. PubMed ID: 7246580
[TBL] [Abstract][Full Text] [Related]
12. Skeletal metastasis of prostate adenocarcinoma in rats: morphometric analysis and role of parathyroid hormone-related protein.
Blomme EA; Dougherty KM; Pienta KJ; Capen CC; Rosol TJ; McCauley LK
Prostate; 1999 May; 39(3):187-97. PubMed ID: 10334108
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of high-dose fosfestrol in hormone-refractory adenocarcinoma of the prostate.
Droz JP; De Smedt E; Kattan J; Keuppens F; Khoury S; Mahler C; Denis L
Prostate; 1994; 24(2):62-6. PubMed ID: 7508621
[TBL] [Abstract][Full Text] [Related]
14. Parathyroid function and vitamin D status in patients with bone metastases of prostatic origin.
Charhon SA; Chapuy MC; Delvin EE; Meunier PJ
Miner Electrolyte Metab; 1985; 11(2):117-22. PubMed ID: 3838794
[TBL] [Abstract][Full Text] [Related]
15. Hypocalcemia due to avid calcium uptake by osteoblastic metastases of prostate cancer.
Szentirmai M; Constantinou C; Rainey JM; Loewenstein JE
West J Med; 1995 Dec; 163(6):577-8. PubMed ID: 8553652
[No Abstract] [Full Text] [Related]
16. Hypocalcemia in a Patient with Cancer.
Rosner MH
Clin J Am Soc Nephrol; 2017 Apr; 12(4):696-699. PubMed ID: 28274993
[No Abstract] [Full Text] [Related]
17. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
Lee YP; Schwarz EM; Davies M; Jo M; Gates J; Zhang X; Wu J; Lieberman JR
Cancer Res; 2002 Oct; 62(19):5564-70. PubMed ID: 12359769
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
[TBL] [Abstract][Full Text] [Related]
19. Hypocalcemia following pamidronate administration for bone metastases of solid tumor: three clinical case reports.
Champallou C; Basuyau JP; Veyret C; Chinet P; Debled M; Chevrier A; Grongnet MH; Brunelle P
J Pain Symptom Manage; 2003 Feb; 25(2):185-90. PubMed ID: 12590034
[TBL] [Abstract][Full Text] [Related]
20. Metabolic studies in a case of hypocalcemia and osteoblastic metastases.
Tommaso CL; Tucci JR
Arch Intern Med; 1979 Feb; 139(2):238-41. PubMed ID: 219791
[No Abstract] [Full Text] [Related]
[Next] [New Search]
